BioSpace News Archive

Neurosurgeons who are attending the Congress of Neurological Surgeons (CNS) Annual Meeting in San Francisco, CA, from October 21st -23rd will have the opportunity to experience Surgical Theater’s SynchronizAR™ intraoperative platform, which aligns patient-specific Precision VR® reconstructions with a live optical image from the surgical microscope.

The report, permanent artificial skin market 2019-2023, has been added to Technavio’s catalog. It provides a comprehensive analysis of the market, including its global and regional market share as well as market segmentation based on end-user and geography for the forecast period 2019-2023.

Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved its novel AMZEEQTM (minocycline) topical foam, 4%.

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, November 1, 2019 to discuss its third quarter operating results

Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases, announced that its scientific team will be presenting preclinical safety, pharmacokinetic and biomarker pharmacodynamic data at the American College of Chest Physicians’ annual CHEST 2019 meeting being held October 19 - 23 in New Orleans, Louisiana.

Spark Biomedical, Inc., a neurostimulation device company developing solutions for opioid withdrawal, received a $217,690 SBIR grant from the National Institutes of Health HEAL initiative.

Out of an abundance of caution, Johnson & Johnson Consumer Inc. announced that it is initiating a voluntary recall in the United States of a single lot of its Johnson’s Baby Powder in response to a U.S. Food and Drug Administration test indicating the presence of sub-trace levels of chrysotile asbestos contamination in samples from a single bottle purchased from an online retailer.

Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for KALYDECO® (ivacaftor), to include use in infants with cystic fibrosis (CF) ages 6 months to less than 12 months who have one of the following mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R.

SOPHiA GENETICS, leader in Data-Driven Medicine, announced today at the American Society of Human Genetics Annual Meeting (ASHG) the release of the new version of SOPHiA Whole Exome Solution.

The Shirley Ryan AbilityLab today hosts a symposium in Chicago to celebrate the pioneering work of UCLA’s Prof. Reggie Edgerton.